Breaking Down Ra Medical Systems, Inc. (RMED) Financial Health: Key Insights for Investors

Curious whether Ra Medical Systems, Inc. (RMED) is a turnaround story or a cautionary tale? Current market ticks show a stock price of $2.235 (down $0.23, -0.09%) with an intraday high/low of $2.45/$2.20 and 59,984 shares traded, while the company reported full-year revenue of $420,000 for 2024 (down from $442,000) and a markedly improved but still negative net loss of $21.8 million versus a $70.57 million loss in 2023; operating income swung to -$11.24 million and operating margin to -2.68% in 2024 from -$78.12 million and -17.68% a year earlier, even as the firm shifts focus to the VIVO line and LockeT devices after divesting Pharos; balance-sheet pressures remain visible with total assets of $25.56 million against liabilities of $19.01 million and a high debt-to-equity ratio of ~2.9, while liquidity is strained with a current ratio of 0.44 and quick ratio of 0.39-factors reflected in an 86.8% six-month and 92.7% one-year stock decline and a negative EPS of -$3.83-read on to drill into the revenue drivers, financing moves, valuation quirks (including a November 7, 2025 price of $0.59 and a startling fair value estimate of -$44.64), and the risks and growth avenues that matter to investors.

Ra Medical Systems, Inc. (RMED) - Revenue Analysis

Real-time market snapshot and intraday context for Ra Medical Systems, Inc. (RMED):

Key revenue-focused observations investors should weigh given the market context above:

• Price action: Current sub-$3 trading indicates market assigns modest near-term growth expectations; volatility within the session (2.20-2.45) suggests limited buying conviction.
• Liquidity: Intraday volume ~60k shares-adequate for occasional trades but may be thin for large institutional moves; watch for volume spikes on news or earnings.
• Market timing: The latest trade at 17:15 PST shows after-hours/late-session activity; after-hours trades can reflect news or sentiment shifts that impact reported revenue guidance and analyst reaction.

Revenue drivers and the analytical lens to apply when assessing Ra Medical Systems, Inc. (RMED):

• Top-line sensitivity: For small-cap med-tech firms, reported revenue growth (quarter-over-quarter and year-over-year) can be lumpy-compare device sales, recurring consumables, and service/license revenue separately.
• Bookings vs recognized revenue: Monitor backlog, order intake, and deferred revenue disclosures-these presage future recognized revenue and help interpret short-term share-price moves.
• Gross margin dynamics: Changes in product mix, manufacturing scale, and discounting materially affect reported gross margins and therefore operating leverage.
• Cash vs revenue runway: With lower share prices, capital access may be constrained; investors must reconcile cash burn and financing needs against revenue trajectory.

Practical signals to watch in upcoming releases and events:

• Quarterly revenue beat/miss vs consensus and any revision to full-year revenue guidance.
• Management commentary on the pace of commercial adoption, reimbursement developments, and channel expansion.
• Any capital raises or convertible issuances that could dilute equity and impact per-share revenue metrics.
• Clinical or regulatory milestones that materially change addressable market assumptions.

For background on the company's business model and longer-term revenue context, see: Ra Medical Systems, Inc. (RMED): History, Ownership, Mission, How It Works & Makes Money

Ra Medical Systems, Inc. (RMED) - Profitability Metrics

• 2024 total revenue: $420,000
• 2023 total revenue: $442,000
• Q2 2025 revenue: $93,000
• Primary revenue headwinds: Pharos divestiture (Q3 2024)
• Strategic growth focus: VIVO product line and LockeT devices

• Net loss 2024: $21.8 million (improved from $70.57 million in 2023)
• Net loss Q2 2025: $4.6 million
• Improvement drivers: cost reductions, fewer legacy-product operating costs following divestiture

• Drivers: leaner cost structure post-divestiture, commercialization efforts for VIVO, introduction of LockeT suture retention/closure devices.
• Short-term risk: reduced revenue base due to sale of Pharos dermatology business; potential timing lag before VIVO/LockeT scale revenue.
• Potential upside: successful market adoption of VIVO and LockeT could materially increase recurring revenue versus legacy dermatology sales.

Ra Medical Systems, Inc. (RMED) - Debt vs. Equity Structure

• The operating income move from -$78.12M to -$11.24M is the largest driver of margin improvement, reflecting cost control and/or revenue recovery.
• Operating margin improvement to -2.68% indicates the company is approaching break-even operationally but remains slightly unprofitable on core operations.
• Net loss narrowed to -$21.8M, a substantial year-over-year reduction that improves cash burn outlook and investor confidence.

• Negative ROE of -3.63% in 2024 signals the company is not generating positive returns on shareholders' equity; equity holders are not receiving profits from invested capital.
• A negative ROE typically arises from net losses or low equity base; for RMED it reflects ongoing net losses despite improvement.
• Capital structure implications:
  • If RMED maintains or grows leverage while ROE is negative, equity dilution or higher interest burden could exacerbate returns pressure.
  • Improving operating income and narrowing net loss reduce the need for immediate dilutive financing and can provide flexibility to manage debt maturities or seek favorable credit terms.

• Cost reduction and efficiency programs likely contributed to the operating income swing; management cites strategic initiatives to further improve profitability.
• Revenue recovery strategies - e.g., expanded sales channels, new product adoption, reimbursement optimization - aim to convert operating improvements into positive net income and ROE.
• Balance sheet management - prioritizing cash preservation, targeted financing, and potential equity raises only if necessary to support growth investments.

Ra Medical Systems, Inc. (RMED) - Liquidity and Solvency

• Total assets (6/30/2025): $25.56 million
• Total liabilities (6/30/2025): $19.01 million
• Shareholders' equity (calculated): $6.55 million
• Debt-to-equity ratio (6/30/2025): ~2.9

• Recent financing history highlights: Q2 2022 ATM ($7.6M) and Q1 2023 private placement ($8.0M), among other financings to support operations and strategy.
• Implications of current structure:
  • High leverage can constrain financial flexibility and increase interest and covenant exposure.
  • Equity cushion is limited (approx. $6.55M), making future downturns or cash shortfalls more acute.
  • Dependence on capital markets or dilutive financings may continue if operating cash flow remains insufficient.
• Key solvency calculation (rounded):
  • Equity = Assets - Liabilities = $25.56M - $19.01M = $6.55M
  • Debt-to-Equity = Liabilities / Equity = $19.01M / $6.55M ≈ 2.9

Ra Medical Systems, Inc. (RMED) - Valuation Analysis

Liquidity and solvency are central to assessing Ra Medical Systems, Inc. (RMED) valuation. Key short-term coverage metrics as of June 30, 2025, highlight near-term funding constraints that investors should weigh against strategic actions management is taking to stabilize the balance sheet and position the company for growth.

• Current ratio (6/30/2025): 0.44 - indicates current assets cover less than half of current liabilities, signaling potential liquidity concerns.
• Quick ratio (6/30/2025): 0.39 - shows limited ability to cover short-term obligations using liquid assets (excludes inventories).
• Active cash-flow management - management is prioritizing working-capital optimization and timing of cash outflows to support operations and strategic initiatives.

• Impacts on valuation multiples: depressed liquidity metrics tend to pressure multiples (higher risk premium); improvement from divestiture or successful financing could compress that premium.
• Value drivers to monitor:
  • Realized benefits from the Pharos divestiture (cost savings, proceeds applied to liabilities)
  • Trajectories in operating cash flow and free cash flow
  • Access to capital markets or strategic partners to shore up the balance sheet
• Scenario sensitivities: a modest improvement in liquidity (current ratio rising toward 1.0) would materially lower perceived solvency risk and support higher valuation multiples; failure to secure financing or realize divestiture benefits would sustain discounting for liquidity risk.

For context on corporate direction tied to these financial actions, see: Mission Statement, Vision, & Core Values (2026) of Ra Medical Systems, Inc.

Ra Medical Systems, Inc. (RMED) - Risk Factors

• Market price: $0.59
• Fair value estimate: -$44.64 (negative, implying valuation models view intrinsic value as below zero)
• Price-to-earnings (P/E) ratio: 0.22
• Earnings per share (EPS): -$3.83 (negative, ongoing net losses)
• 6‑month price change: -86.8%
• 1‑year price change: -92.7%

• The negative fair value indicates valuation models (discounted cash flow or similar) project liabilities, cash burn, or future cash flows that render the intrinsic value below zero - a strong red flag for fundamental investors.
• A P/E of 0.22 alongside negative EPS suggests distorted multiples: either the reported earnings base is anomalous or the ratio reflects accounting oddities; investors should treat P/E here with caution.
• Severe share price declines (near 90%+ across 6-12 months) reflect market loss of confidence, potential liquidity concerns, or material adverse developments.
• Negative EPS confirms the company is not profitable on a trailing basis, increasing the reliance on external financing or asset sales to sustain operations.

• Capital risk: ongoing losses (EPS -$3.83) increase likelihood of dilution through equity raises or unfavorable debt.
• Liquidity and solvency risk: a negative fair value suggests models expect liabilities/exposure to exceed value; potential bankruptcy or restructuring risk exists if cash burn continues.
• Market confidence risk: extreme share declines (86.8% six months; 92.7% one year) can trigger delisting risk, margin pressures, and shrink investor base.
• Valuation-metric distortion: contradictory metrics (very low P/E vs. negative EPS) may mislead momentum traders; fundamentals do not support multiple-driven rallies.
• Execution risk: rebuilding path to profitability is uncertain and contingent on commercial traction, cost control, and access to financing.

Ra Medical Systems, Inc. (RMED) - Growth Opportunities

• Integration of Catheter Precision: successful technical and commercial integration could expand procedural indications and addressable market; failure risks wasted R&D and lost market momentum.
• Post-divestiture focus: shedding Pharos dermatology assets may sharpen management focus on vascular and catheter-based therapies but could reduce near-term revenue diversification.
• Single-product dependency: a concentration on the primary ablation/catheter platform increases revenue volatility tied to adoption, reimbursement, and clinical outcomes.
• Competitive pressures: established medical-device firms and agile newcomers create pricing, reimbursement, and market-share challenges.
• Capital structure and liquidity: elevated leverage and weak short-term coverage metrics limit strategic flexibility and raise refinancing risk.

• Liquidity implications: with ~ $12M cash and a quarterly burn near $10M, runway without new capital or improved cash flow is limited to roughly one quarter, heightening refinancing or equity dilution risk.
• Leverage implications: a 2.5x debt-to-equity ratio increases interest burden and covenant exposure; any revenue shortfall could force restructuring or asset sales.
• Operational concentration: revenue tied to a narrow product set amplifies sensitivity to procedure volumes, reimbursement shifts, and competitive product launches.
• Integration risk specifics: merging Catheter Precision technology requires capital for regulatory filings, training, and clinical validation; delays could defer expected revenue synergies.

• Quarterly cash balance and operating cash flow trend.
• Progress on Catheter Precision clinical/regulatory milestones and commercial launches.
• Any debt refinancing, covenant waivers, or capital raises (equity or convertible financings).
• Revenue concentration metrics and contribution from any new product lines post-divestiture.
• Competitive wins, reimbursement updates, and adoption rates in target procedure categories.